Table 1 Aβ-positive cohort's demographics and biomarker levels
| Â | Mutation carriers | Non-carriers AD | ||
|---|---|---|---|---|
All | PTC carriersa | VNTR expansion carriersa | ||
Samples (n) | ||||
 Aβ+ | 36 | 23 | 13 | 127 |
 AAO | 72.9 (10.3) | 71.3 (10.9) | 75.8 (8.7) | 75.6 (8.1) |
Sex | ||||
 Male | 14 (38.9%) | 10 (43.5%) | 4 (30.8%) | 45 (35.4%) |
 Female | 22 (61.1%) | 13 (56.5%) | 9 (69.2%) | 82 (64.6%) |
APOE ε4 | ||||
 Positive | 24 (66.7%) | 16 (69.6%) | 8 (61.5%) | 75 (59.1%) |
 Negative | 12 (33.3%) | 7 (30.4%) | 5 (38.5%) | 52 (40.9%) |
Biomarkers (n) | ||||
 Aβ1–42 (pg/mL) | 490.5 (273.3) | 535 (345.5) | 385 (228) | 578 (308) |
 Aβ1–40 (pg/mL) | 5957.5 (3734.3) | 6638 (4086.5) | 4405 (1431) | 6738 (3088.5) |
 Aβ ratio | 0.089 (0.033) | 0.081 (0.026) | 0.09 (0.04) | 0.09 (0.03) |
 sAPPα (ng/mL) | 97.5 (66.3) | 119 (85.5) | 83 (27) | 113.5 (74.8) (n = 126) |
 sAPPβ (ng/mL) | 93.5 (72.5) | 110 (84.5) | 82 (20) | 117 (83) |
 YKL-40 (ng/mL) | 187 (90) | 208 (80) | 150 (45) | 201 (112.5) |
 hFABP (ng/mL) | 4.39 (2.8) | 4.86 (2.37) | 3.2 (2.9) | 4 (1.8) (n = 126) |
 T-tau (pg/mL) | 619 (544) (n = 29) | 723 (386) (n = 17) | 464 (475.5) (n = 12) | 548 (428) (n = 112) |
 P-tau181 (pg/mL) | 70 (53) (n = 29) | 76 (45) (n = 17) | 60.5 (57.8) (n = 12) | 81 (47.5) (n = 111) |